scholarly journals Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation 

2009 ◽  
Vol 24 (9) ◽  
pp. 2238-2243 ◽  
Author(s):  
M. Sanchez-Serrano ◽  
E. Novella-Maestre ◽  
E. Rosello-Sastre ◽  
N. Camarasa ◽  
J. Teruel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Malignant Cells ◽  
Breast Cancer Patients ◽  
Ovarian Cortex ◽  
Ovarian Cortex Cryopreservation

scholarly journals An in vitro method to select malignant cells from surgical biopsies of breast cancer patients

2005 ◽  
Vol 7 (1) ◽  
pp. 8-16 ◽  
Author(s):  
Kelly E. Corcoran ◽  
Prem S. Patel ◽  
Pranela Rameshwar
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Malignant Cells ◽  
Breast Cancer Patients ◽  
In Vitro Method

Effect of primary polychemotherapy after sentinel lymph node biopsy on the necessity for lymphadenectomy in stage II breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11589-e11589
Author(s):  
U. Bohn ◽  
M. Pavcovich ◽  
P. Jimenez ◽  
M. Hernandez ◽  
M. Lloret ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Tumour Response ◽  
Stage Ii ◽  
Primary Chemotherapy ◽  
Malignant Cells ◽  
Breast Cancer Patients

e11589 Background: Sentinel lymph node (SLN) biopsy is the standard procedure for assessing axillary status in stage I-II breast cancer patients. Realizing this procedure before the administration of primary polichemotherapy would reduce the number of unnecesary lymphadenectomy in patients with negative sentinel lymph node. Methods: From January 2006 to May 2008, twenty-one patients with breast cancer on stage II-IIIA were included in the study. The median age was of 49 years (range 22–74y). The median palpable tumour size was of 3.5cm (range 1.8–6.0) and by ultrasonography 2.0cm (range 1.8–5.0cm.). Stage II:19 and Stage III:2 (cT:6.0cm.). Breast biopsy was performed in all cases with: IDC:20. G1:9 (42,8%), G:2:11(52%) and G3:1(4,76%). ER+:18 (85,7%), PR+:13 (61,9%), HER2 (+):6 (28,5) and triple negative:3 (14,2%).The scheme of treatment was: 4Epi: 90mg/M2 and Cyclophosphamide 600mg/M2 day 1/3w/4cycles, followed by paclitaxel (P) 100mg/M2 day 1/wekly/8. Trastuzumab was given during one year 4/2mg/Kg and started with (P). Tumorectomy and limphadenectomy was planned, followed by radiotherapy ± Hormonotherapy ± trastuzumab. Results: The 21 patients were evaluable for the analysis. The median sentinel lymph nodes resected was of 2 (range 2–6). The SLN biopsy was positive in 12 (57,1%) cases and negative in 9 (42,8%). Followed the primary chemotherapy, tumorectomy and axillary lymphadenectomy (AL) were performed in all 21 cases. The 12 positive SLN showed in the AL 9/12 (75%) pN0 and the 9 negative SLN showed in the AL 0/9 (0%) pN1. There were 4/20 (20%) completely pathological tumour response and 4/20 (20%) cases with only isolated malignant cells. The treatment was well tolerated with not a case of grade 3–4 toxicity. Conclusions: The primary chemotherapy given after the biopsy of sentinel lymph node was very effective showing in the lymphadenectomy a high percentage of pathologic negative lymph nodes (9/12) and an overall tumour response of 40% (8/20) with 4/20 (20%) completely pathological response and 4/20 (20%) cases with only isolated malignant cells. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document